The SWIPE 2 Trial
Research type
Research Study
Full title
Small volume fluid resuscitation and supplementation with 20% albumin versus buffered crystalloids in patients with septic shock: A randomised feasibility trial.
IRAS ID
1005399
Contact name
Jonathan Bannard-Smith
Contact email
Sponsor organisation
Manchester University NHS Foundation Trust
Eudract number
2022-000997-24
Clinicaltrials.gov Identifier
Research summary
Background to this research
Sepsis is the most severe type of infection. It happens when a patient’s immune system is fighting an infection, but
causes damage or even failure to vital organs. Septic shock is a term used to describe the worst form of sepsis,
where patients need life-supporting treatments in intensive care.Guidelines recommend doctors give fluid to patients with sepsis. This aims to improve blood flow to vital organs, and
reduce the risk of further damage. However, there maybe risks if patients are given too much fluid, such as
developing kidney failure or even death.Albumin is a type of fluid, made from blood donated by healthy volunteers. Alternative fluids include solutions of salts
and water that closely match the contents of human blood. Some research suggests patients with sepsis might
benefit from being given albumin, particularly those with septic shock.The overall aims of this research
The aim of this research is to test whether it is feasible to compare albumin with salt solutions in patients with septic
shock.What will happen in this research?
We will conduct a feasibility study of 50 patients who are admitted to intensive care with septic shock. Patients will be
randomly divided into two groups. One group will receive albumin and the other standard salt solutions.
Participating patients will provide blood samples shortly after their arrival in intensive care and also 2 and 5
days later. All other aspects of care and treatment will remain the same. Patients will be observed and followed up to
see how they are 3 months after entering the study.What will happen with the results?
The results of this study will help us move forward with further research into how albumin maybe used cost-effectively
in patients with sepsis in the NHS.REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
22/NW/0361
Date of REC Opinion
29 Mar 2023
REC opinion
Further Information Favourable Opinion